1. Home
  2. MX vs SPRO Comparison

MX vs SPRO Comparison

Compare MX & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnachip Semiconductor Corporation

MX

Magnachip Semiconductor Corporation

HOLD

Current Price

$3.66

Market Cap

139.1M

Sector

Technology

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$1.28

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MX
SPRO
Founded
2003
2013
Country
South Korea
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.1M
156.3M
IPO Year
2007
2017

Fundamental Metrics

Financial Performance
Metric
MX
SPRO
Price
$3.66
$1.28
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$5.75
N/A
AVG Volume (30 Days)
1.4M
1.9M
Earning Date
04-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
43.06
111.81
EPS
N/A
N/A
Revenue
$178,860,000.00
$66,802,000.00
Revenue This Year
$8.55
N/A
Revenue Next Year
$6.37
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$2.18
$1.37
52 Week High
$9.86
$3.08

Technical Indicators

Market Signals
Indicator
MX
SPRO
Relative Strength Index (RSI) 39.32 20.44
Support Level $2.45 N/A
Resistance Level $4.76 $2.44
Average True Range (ATR) 0.28 0.15
MACD -0.00 -0.07
Stochastic Oscillator 28.17 0.46

Price Performance

Historical Comparison
MX
SPRO

About MX Magnachip Semiconductor Corporation

MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The Company operates within a single operating segment, Power Solutions business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: